SBIR Phase II: An Innovative Full-Thickness Human Skin Model for Increased Throughput Screening in Drug Discovery

Award Information
Agency: National Science Foundation
Branch: N/A
Contract: 1058591
Agency Tracking Number: 1058591
Amount: $499,877.00
Phase: Phase II
Program: SBIR
Awards Year: 2011
Solitcitation Year: 2011
Solitcitation Topic Code: Phase II
Solitcitation Number: N/A
Small Business Information
Stratatech Corporation
505 South Rosa Road, Suite 169, Madison, WI, 53719-1267
Duns: 160392168
Hubzone Owned: N
Woman Owned: Y
Socially and Economically Disadvantaged: N
Principal Investigator
 Kenneth Gratz
 (608) 441-2756
 kgratz@stratatechcorp.com
Business Contact
 Kenneth Gratz
Title: DPhil
Phone: (608) 441-2756
Email: kgratz@stratatechcorp.com
Research Institution
 Stub
Abstract
This Small Business Innovation Research (SBIR) Phase II project proposes to develop a high-throughput assay incorporating 3-D skin models capable of accurately identifying and characterizing DNA damage. There is an urgent need for improved genotoxicity assays for safety screening in drug development. The process by which drug compounds are usually screened is expensive, time-consuming, and often does not provide an accurate depiction of in vivo behavior. Phase I of this project developed a full-thickness skin model that can be used in a range of toxicological assays. Phase II will address the limitations of current genotoxicity assays by incorporating fluorescent reporter constructs into the 96-well skin model to create an assay that is high-throughput and accurately distinguishes between classes of genotoxins. The broader impacts of this research are to develop a genotoxicity screen that is more informative, accurate, and high-throughput than existing alternatives. Development of accurate in vitro assays not only reduces the need for animal testing, but can also reduce the risk to patients included in clinical trials by providing better predictions of the human response. Toxicity has become one of the leading reasons for product failure during drug development. The ability for this assay to identify and eliminate harmful compounds earlier in the development process could significantly reduce the costs and accelerate the timeline of drug development. In addition to these direct contributions for drug and chemical screening, the mechanistic data provided by this assay will provide a valuable tool for basic science research into DNA damage.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government